Flexible-dose clinical trials: Predictors and outcomes of antipsychotic dose adjustments

Journal of Clinical Psychopharmacology

Volumn 25, Issue 4, 2005, Pages 381-386

  Lipkovich, Ilya ^a   Baron, David ^b   Houston, John ^a   Ahl, Jonna ^a   Rotelli, Matthew ^a  

^a ELI LILLY AND COMPANY   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; RISPERIDONE;

AKATHISIA; ARTICLE; BIPOLAR I DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 23044458349     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000167791.70664.d4     Document Type: Article

References (9)

1. Tohen M, Goldberg JF, Gonzalez-Pinto AAM, et al. A 12-week double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry. 2003;60(12):1218-1226.
2. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1977;17(5):407-418.
3. Tohen M, Bowden C, Calabrese J, et al. Olanzapine versus placebo for relapse prevention in bipolar disorder. Presentation at the Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 17-22, 2003.
4. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429-435.
5. Kay SR, Fisbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276.
6. Guy W, ed. ECDEU Assessment Manual for Psychopharmacohgy: Publication Adm 76-338. Washington, DC: US Department of Health, Education, and Welfare; 1976:534-537.
7. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
8. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Act Psychiatr Scand Suppl. 1970;212:11-19.
9. Day RK. Psychomotor agitation: poorly defined and badly measured. J Affect Disord. 1999;55:89-98.